The People of The State of New York v. Actavis plc et al, No. 1:2014cv07473 - Document 43 (S.D.N.Y. 2014)

Court Description: OPINION re: 37 MOTION to Seal / Notice of Defendants' Motion to Seal 35 MEMORANDUM OF LAW. filed by Forest Laboratories, L.L.C., Actavis plc. The motion of the Defendants to maintain the sealing of the redacted portions of the Complaint is granted in part and denied in part as set forth above. It is so ordered. (See Order.) (Signed by Judge Robert W. Sweet on 10/21/2014) (ajs)

Download PDF
The People of The State of New York v. Actavis plc et al Doc. 43 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK --------------------------------------x THE PEOPLE OF THE STATE OF NEW YORK, Plaintiff, -against- 14 Civ. 7473 OPINION ACTAVIS, PLC, and FOREST LABORATORIES, LLC, Defendants. --------------------------------------x A P P E A R A N C E S: Attorneys for Plaintiff NEW YORK STATE OFFICE OF THE ATTORNEY GENERAL 120 Broadway, 26th Floor New York, NY 10271 By: Elinor R. Hoffmann, Esq. Attorneys for Defendants WHITE & CASE LLP 1155 Avenue of the Americas New York, NY 10036 By: Jack Pace, Esq. Martin Michael Toto, Esq. Peter J. Carney, Esq. Dockets.Justia.com Sweet, D.J. Defendants Forest Laboratories, LLC ("Forest") and Actavis, PLC ("Actavis") (collectively, the "Defendants") have moved to maintain under seal, as confidential, cornrnerciallysensitive information, portions of the Complaint filed by the People of the State of New York (the "State" or the "Plaintiff") . Based on the conclusions set forth below, the motion is granted in part and denied in part. Prior Proceedings On February 28, 2014, the Antitrust Bureau of the Office of the Attorney General of the State of New York (the "Bureau") opened an investigation into Forest's business plans regarding the pharmaceutical product Namenda, an FDA-approved therapy to treat Alzheimer's disease. million pages of documents Forest produced over 1.7 (pursuant to three subpoenas), three executives to provide investigational testimony, written interrogatory responses, and additional items that the Bureau requested informally. Forest produced this information designated as "Highly Confidential" and requested that any of 1 the produced information used in any proceeding be filed under seal. On September 15, 2014, the State filed its Complaint relating to the Bureau's investigation, referencing documents and testimony provided by Forest during the investigation. Counsel for Defendants immediately notified the Bureau of the Defendants' confidentiality concerns and requested that the Complaint be refiled with the proposed redactions. The State agreed to file its Complaint on September 19 with the redactions requested by the Defendants. The Complaint alleges that Defendants violated federal and state antitrust laws by attempting to improperly maintain and extend a monopoly over the drug they developed to treat Alzheimer's disease. The Complaint seeks injunctive relief requiring Defendants to keep the original form of the drug, Namenda lR, on the market and to prevent the Defendants from seeking to switch patients to a new patent-protected form, Namenda XR. 2 The Complaint describes: the parties (Compl. ｾ＠ 12- 15); the regulatory framework and relevant federal regulations, including the Food Drug and Cosmetic Act, 21 USC§ 301 et seq., the Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585, the Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-115, 111 Stat. 2296 (Compl. Laws (Compl. ｾ＠ 16-20); the State Generic Substitution 21-27); and the effect of generic competition ｾ＠ and brand name manufacturers' tactics to evade them (Compl. ｾ＠ 28-43), including the practice of "product hopping," which the Defendants are alleged to be contemplating in order to avoid the "patent cliff." The Complaint also describes: Alzheimer's disease and the relevant products (Compl. ｾ＠ 46-63) (Compl. 44-45); and the relevant market ｾ＠ including Memantine that is branded and marketed as Namenda by Defendants, Namenda's recent sales of $1.5 billion in the United States, the extension of the Namenda patents, and the anticipated entry of generic competition in July 2015. The Complaint further alleges that the Defendants have made efforts to stall the effects of generic entry in the market (Compl. ｾ＠ 64-97), including the launch of Namenda XR in June 2013 and the effort to convert patients from Namenda IR to 3 Namenda XR and the plan to force switches. The Complaint alleges the anticompetitive effect of the conduct of the Defendants (Compl. ]] 98-104) and their conduct in exaggerating the imminence of the plan to force switches (Compl. Five causes of action are alleged: in violation of Section 2 of the Sherman Act; ｾ＠ 105-117). (1) monopolization (2) attempted monopolization in violation of Section 2 of the Sherman Act; (3) violation of the Donnelly Act, New York General Business Law Section 340 et seq.; (4) repeated or persistent illegality in violation of Section 63(12) of the New York Executive Law; and (5) repeated or persistent fraud, in violation of Section 63(12) of New York Executive Law. The Defendants' motion to maintain the sealed portions of the Complaint was heard and marked fully submitted on September 24, 2014. The Standard for Sealing In re James, Hoyer, Newcomer, Smiljanich and Yanchunis, P.A., illustrates the policy considerations at the heart of this motion: 4 [A producing party ("Party")] requested at the time the documents were produced to the [Office of the Attorney General ("OAG") ], that all the documents be maintained as confidential and exempt from disclosure under FOIL. [The Party's] expectation of confidentiality was specifically discussed with the OAG at the time. This expectation of confidentiality for these documents was very important in the [Party's] decision to cooperate with the OAG's investigation. It would violate that expectation, and probably deter future cooperation by [the Party] and other affected entities, if any of [the Party's] documents were now released. [But in] today's era . free access to information is even more critical as a fundamental step in protecting consumers. Index No. 114184/09, 2010 WL 1949120, at *1, *6 (N.Y. Sup. Ct. Mar. 31, 2010) . On the one hand, as the court in In re Crowley Food, Inc. noted: There is a sound rationale for the requirement of confidentiality. If there were no confidentiality in antitrust investigations, those who were the subjects of an investigation would be 'tarred with the taint' of having violated the antitrust laws even though that may not be the case. It would be analogous to announcing the empaneling of a grand jury to investigate one's activities. It implies a suspicion of guilt. 5 Index No. 119316, 1979 WL 18648, at *6 (N.Y. Sup. Ct. Mar. 10, 197 9) . Similarly, in federal antitrust cases, the government regularly filed documents under seal or with confidential information redacted. See, e.g., Br. for Appellant United States of America (Redacted), United States v. AMR Corp., 335 F.3d 1109 (2002) (No. 01-3202) (available at Permission to File Competitively Sensitive Information under Seal and for an Interim Protective Order, United States v. Sungard Data Sys., Inc., 172 F. Supp.2d 172 0219 6) (2001) (No. 01- (available at File under Seal, United States v. The Home City Ice Co. (No. 07-140) (2007) (available at h"ttE://www. ustice. /atr cases/f234200/234206.htm). ... -. ............................................... - ··········································· ...... On the other hand, there is a strong presumption of public access to federal court filings under the common law and the First Amendment. See Lugosch v. Pyramid Co. of Onondaga, 435 F.3d 110, 120-21 (2d Cir. 2006) (for judicial documents, "a strong presumption of access attaches, under both the common law 6 and the First Amendment"). Once First Amendment protection extends to a court filing, "continued sealing of the documents may be justified only with specific, on-the-record findings that sealing is necessary to preserve higher values and only if the sealing order is narrowly tailored to achieve that aim." Id. at 124; see also In re Parmalat Sec. Litig., 258 F.R.D. 236, 244 (S.D.N.Y. 2009) (sealing requires "particular and specific demonstration of fact showing that disclosure would result in an injury sufficiently serious to warrant protection; broad allegations of harm unsubstantiated by specific examples or articulated reasoning fail to satisfy the test") (internal citations and quotations omitted). A party wishing to seal materials has the burden to show good cause as to why the material should be concealed from the public. See Parmalat, 258 F.R.D. at 241. Courts can seal "business information that might harm a litigant's competitive standing" in the market. See id. at 244. However, "the fact that business documents are secret or that their disclosure might result in adverse publicity does not automatically warrant a protective order." Id.; see also Salomon Smith Barney, Inc. v. HBO & Co., 98 Civ. 8721, 2001 WL 225040, at *2 7, 2001) (S.D.N.Y. Mar. (denying motion to remove documents from the public 7 court file where "[the movant]'s real concern is the possibility of public embarrassment."). Internal documents and unpublished drafts that contain non-public strategies and financial information constitute "confidential commercial information" under Federal Rule 26 (c) (1) (g), particularly where the disclosing company is engaged in a highly competitive industry and deliberately has shielded such information from its competitors. See, e.g., Fox News Network v. U.S. Dep't of Treas., 739 F. Supp. 2d 515, 571 (S.D.N.Y. 2010) (withholding draft containing proposed financial and risk reporting strategy); Brittain v. Stroh Brewery Co., 136 F.R.D. 408, 415-416 (M.D.N.C. 1991) ("Such commercial information, which encompasses strategies, techniques, goals and plans, can be the lifeblood of a business [and] may also be particularly deserving of protection if the disclosing corporation is vulnerable to competitors."). Cost data is sensitive and potentially damaging if shared with competitors. See Vesta Corset Co. v. Carmen Founds., Inc., 97 Civ. 5139, 1999 WL 13257, at *2 13, 1999) (S.D.N.Y. Jan. (noting protocol to treat parties' cost information as confidential and holding, "Pricing and marketing information are 8 widely held to be 'confidential business information' that may be subject to a protective order"); Support Sys. Assocs. Inc. v. Tavolacci, 135 A.D.2d 704, 522 N.Y.S.2d 604, 605-06 (N.Y. App. Div. 1987) ("pricing and cost information provided to [defendant] was ... confidential because if it were known to competitors, they would be in a position to underbid the plaintiff"). Marketing and promotional expenses are sensitive and can be damaging if shared with competitors and customers, depending "upon: 1) the extent to which information is known outside the business; 2) the extent to which information is known to those inside the business; 3) the measures taken to guard the secrecy of the information; and 4) the value of the information to the business and its competitors." Vesta, 1999 WL 13257, at *2. Applying the standard set forth above, courts grant confidential treatment under circumstances where trade secrets and material that would place a party at a competitive disadvantage are being used in public filings. 9 Confidential Treatment is Granted in Part and Denied in Part As described above, certain allegations which the Defendants have asserted are confidential have been redacted in the Complaint filed by the State. The Defendants now seek to have those redactions maintained under seal while, in the main, the State contends that the public interest requires the redactions to be made public. As in Parmalat, 258 F.R.D. at 244, the party seeking the sealing has the burden of establishing the competitive disadvantage. The Defendants have submitted the Ｒｾ＠ page somewhat conclusory affidavit of William Kane, the Vice President Marketing Internal Medicine at Forest for that purpose. The Complaint establishes that the conduct which is challenged here is part of a complicated mosaic resulting from the exclusivity granted to patents, the FDA and state regulations, and the complications of competition between branded drugs and generics in the drug industry. The competition at issue appears to be that between the Defendants and those who may seek to offer to patients generic versions of the Defendants' branded drugs. A complicating factor is that 10 the Defendants' plans for that very competition are the gravamen of the State's Complaint. As to the specific paragraphs at issue: 1 Paragraph 69 The second sentence dealing with profit projections is confidential, the disclosure of which will competitively disadvantage the Defendants. It will be sealed. Paragraph 73 The first bulleted indented paragraph contains a business plan, the disclosure of which could competitively disadvantage the Defendants. It will be sealed. Paragraph 74 The Kane Affidavit fails to establish that this allegation would competitively disadvantage the Defendants. Determinations with respect to redacted allegations in the Complaint do not constitute rulings on evidence relating to substantive issues. 11 Paragraph 75 The redacted portion of the allocation of promotional budget funds, Defendants. if disclosed, would competitively disadvantage the It will be sealed. Paragraph 79 The first sentence contains internal projections, the disclosure of which will competitively disadvantage the Defendants. It will be sealed. Paragraph 82 The State did not oppose this redaction. It will be sealed. Paragraph 83 The disclosure of financial projections of alternative plans would be a competitive disadvantage. 12 It will be sealed. Paragraph 84 The Defendants have contended that the information reflected in this material was later determined to be largely unfounded. No competitive disadvantage has been established. Paragraph 85 No competitive disadvantage has been established. Paragraph 86 The last sentence contains a projection, the publication of which would put the Defendants at a competitive disadvantage. It will be sealed. Paragraph 93 Although the Defendants classify this email as part of their regulatory strategy, and as reflecting confidential information, the disclosure of which would damage customer and contract relations, Kane Aff. ｾ＠ 5-7, no competitive disadvantage has been established. 13 Paragraph 101 These redactions deal with income projections the publication of which would competitive disadvantage the Defendants. They will be sealed. Paragraph 103 The redaction deals with a manufacturing process which must be viewed as common knowledge. No competitive disadvantage to Defendants has been established. Paragraph 108 The redactions concern future plans for the discontinuance of Namenda IR, the publication of which could competitively disadvantage the Defendants. They will be sealed. The Donnelly Act Confidentiality Does Not Warrant Redaction The Defendants also contend that the Donnelly Act (the "Act") requires continued confidentiality with respect to documents they have produced to the State, and the sealing of 14 ---------------------------------------- the redacted portions of the Complaint. The Act provides as follows: Any officer participating in such inquiry [i.e., an antitrust investigation] and any person examined as a witness upon such inquiry who shall disclose to any person other than the attorney general the name of any witness examined or any other information obtained upon such inquiry, except as so directed by the attorney general shall be guilty of a misdemeanor. Such inquiry may upon written authorization of the attorney general be made public. N.Y. Gen. Bus. Law§ 343. The Act permits the "inquiry" to be made public, upon written authorization, but not the "information obtained" in the inquiry. See also id. (authorizing the Bureau to issue subpoenas for "books or papers" that the Bureau deems "relevant or material to the inquiry"). With respect to the Defendants' repeated requests for confidentiality, Plaintiff responded as follows: Finally pertaining to your concerns about protections for trade secrets and certain commercially sensitive information, New York's Freedom of Information Law expressly exempts such material from disclosure - as well as information compiled for law enforcement purposes, e.g., during investigations by our office, N.Y. Public Officer Law, 87 (2) (d), (e). (Ex. 1 to Defs.' Order to Show Cause Sealing Compl.) 15 This provision was not violated during the investigation by the Bureau and did not cloak all the material produced with confidentiality for all time. When the Complaint was filed, N.Y. Gen. Bus. Law§ 343 provided that information and documents obtained in a Donnelly Act investigation may "be made public" upon "authorization of the attorney general." New York courts have affirmed this statutory authority, holding that "[t]he Attorney General ... is expressly authorized by statute, to reveal ... information [obtained in a Donnelly Act investigation] at any time." Ragusa v. New York State Dep't of Law, 578 N.Y.S.2d 959, 963 (N.Y. Sup. Ct. 1991). This is consistent with the Attorney General's power in other areas, such as under the Martin Act. Misc.3d 377, 383 See e.g., New York v. Thain, 24 (N.Y. Sup. Ct. 2009) ("The case law is uniform that the Martin Act vests in the Attorney General the authority to decide whether the information he gathers as part of his investigation should be kept secret or public."). Therefore, the Donnelly Act argument does not alter the analysis as described above. 16 Conclusion The motion of the Defendants to maintain the sealing of the redacted portions of the Complaint is granted in part and denied in part as set forth above. It is so ordered. New ï½ ï½¯ï½²ï½«ï½¾ï¼  October NJ ｾｦＧ＠ 2014 ROBERT W. SWEET U.S.D.J. 17

Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You should read the full case before relying on it for legal research purposes.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.